Michael P. Dwyer - Concepedia

Author

Michael P. Dwyer

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

M. DWYER, M. Dwyer, M. P. DWYER, Michael Dwyer, Michael P Dwyer, Michael P. Dwyer

147

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)WuXi AppTec (China)United States Military Academy The University of Texas at Austin United States Pharmacopeial Convention

About

Michael P. Dwyer is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in drug discovery, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	24	1.5K
2	Natural Sciences	12	14	675
3	Biochemistry	12	14	716
4	Engineering	3	3	284
5	Applied Physics	1	1	53

Michael P. Dwyer

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor David Parry, Timothy J. Guzi, Nicole R. Davis, Molecular Cancer Therapeutics PharmacotherapyCancer BiologyTumor BiologyCdk9 ActivityReceptor Tyrosine Kinase	2010	553
Enantioselective Intramolecular Cyclopropanations of Allylic and Homoallylic Diazoacetates and Diazoacetamides Using Chiral Dirhodium(II) Carboxamide Catalysts Michael P. Doyle, Richard E. Austin, A. S. Bailey, Journal of the American Chemical Society Enantioselective SynthesisEngineeringDonut IconAltmetric Attention ScoreOrganic Chemistry	1995	215
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases Kamil Paruch, Michael P. Dwyer, Carmen Álvarez, ACS Medicinal Chemistry Letters Drug TargetPathologyChemical BiologyPharmaceutical ChemistryTumor Biology	2010	174
Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Molecular Cancer Therapeutics	2011	170
Pharmacological Characterization of Sch527123, a Potent Allosteric CXCR1/CXCR2 Antagonist Waldemar Gonsiorek, Xuedong Fan, David Hesk, Journal of Pharmacology and Experimental Therapeutics	2007	127
Discovery of 2-Hydroxy-<i>N</i>,<i>N</i>-dimethyl-3-{2-[[(<i>R</i>)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): A Potent, Orally Bioavailable CXCR2/CXCR1 Receptor Antagonist Michael P. Dwyer, Younong Yu, Jianping Chao, Journal of Medicinal Chemistry Pharmaceutical ScienceDrug TargetImmunologyPharmacotherapyLead Cyclobutenedione 3	2006	113
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach—Part 2 Marc Labroli, Kamil Paruch, Michael P. Dwyer, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryDrug TargetBiochemistryTemplate-based Approach—part 2	2010	74
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach—Part 1 Michael P. Dwyer, Kamil Paruch, Marc Labroli, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryDrug TargetBiochemistryMedicine	2010	68
Structure‐guided discovery of cyclin‐dependent kinase inhibitors Thierry Fischmann, Alan Hruza, José S. Duca, Biopolymers Molecular DockingMolecular RecognitionMedicinal ChemistryDrug TargetBiochemistry	2007	67
Cyclopropane-Derived Peptidomimetics. Design, Synthesis, and Evaluation of Novel Enkephalin Analogues Stephen F. Martin, Michael P. Dwyer, Benoı̂t Hartmann, The Journal of Organic Chemistry	2000	65

Page 1